Acepodia, a biotech firm in the clinical stages, has released initial findings from its Phase 1 dose escalation trial of ACE1831. This therapy, a fusion of an anti-CD20 antibody with allogeneic gamma delta T cells, is aimed at treating non-Hodgkin's lymphoma

Invivyd, Inc., a biopharmaceutical company specializing in combating severe viral infections, has disclosed its intention to seek emergency use authorization from the U.S. Food and Drug Administration for pemivibart.

TC BioPharm, a biotechnology company in the clinical stage, has recently announced its intention to acquire a privately-held biotechnology company. This company specializes in the development of Chimeric Antigen Receptor T-cell

AsclepiX Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in computational biology from Johns Hopkins to develop peptides for treating retinal diseases, has announced the completion

Gossamer Bio, Inc., a biopharmaceutical company focusing on the clinical development and commercialization of seralutinib for treating pulmonary arterial hypertension and pulmonary hypertension

Amolyt Pharma has received Fast Track designation from the FDA for its Phase 3 development targeting hypoparathyroidism. The Fast Track process expedites drug review for serious conditions with unmet medical needs.

Remix Therapeutics, a biotechnology company in the clinical stage, is pioneering the development of small molecule therapies targeting RNA processing to combat the root causes of diseases. Today, they announced a significant step forward with

Tenax Therapeutics, Inc. has announced that the United States Patent and Trademark Office has granted the company a patent covering the use of several forms of levosimendan,

Wave Life Sciences Ltd. has announced the approval of its first clinical trial application for the RestorAATion-2 trial of WVE-006, a novel RNA editing oligonucleotide designed to treat alpha-1 antitrypsin deficiency

X4 Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved XOLREMDI™ capsules for patients aged 12 and above diagnosed with WHIM syndrome